On this page
What belongs in the nonclinical pharmacology summaries in CTD 2.6.2 and 2.6.3?
The pharmacology summaries explain the product’s intended activity, other pharmacological effects, safety pharmacology and relevant pharmacodynamic interactions. The written account interprets the findings; the tables preserve study context and results. Both should identify the same studies and distinguish a laboratory observation from an established clinical effect.
Before you begin
M4S sections 2.6.2 and 2.6.3; studies actually performed and relevant to the pharmaceutical. A table example is not a universal testing prescription.
What you will prepare: A pharmacology narrative and matching tables that distinguish intended activity from potential unwanted effects.
Sections covered in this guide (2)
Classify the scientific question before summarizing the result
Obtain the final pharmacology reports, assay descriptions, test-material identities and study register. M4S organizes the written summary around primary pharmacodynamics, secondary pharmacodynamics, safety pharmacology and pharmacodynamic interactions, followed by interpretation. Start by asking what question each study addresses.
Do not classify a study solely by its assay name. A result about target activity differs from an evaluation of an unintended organ-system effect. When one study informs more than one question, preserve its single identity and explain the connection rather than creating apparently independent evidence.
Begin the written summary with an orientation to the package and important gaps or unusual choices. A missing model should be discussed with its scientific rationale, not hidden by describing only the available experiments.
Write the narrative and tables as a coordinated pair
For an important finding, identify the system, endpoint, concentration or dose context, controls and limitations that affect interpretation. Explain how primary activity relates to the intended mechanism and how secondary or safety findings affect the overall pharmacological picture. Do not turn a laboratory response into a demonstrated clinical benefit.
In 2.6.3, use the applicable M4S tabulated formats as the starting point, adapting presentation to the evidence. Include a stable study/report identifier and enough experimental context to interpret the result. Confirm that narrative statements can be located in their table and source report.
Use an editorial comparison row for effects discussed across assays: endpoint definition, test system, exposure measure, result, source and limitation. Differences in assay conditions may explain differences in apparent potency; the author should surface those differences for scientific review rather than averaging incompatible values.
Worked example: an off-target result is dropped
Fictional editorial exercise: a compound shows intended receptor activity and a secondary signal in another assay. The summary highlights target selectivity but omits the secondary signal because a later experiment found a smaller effect.
Place both experiments side by side. Check controls, tested concentrations, material and endpoint definition. Ask the pharmacology reviewer whether the later experiment resolves, qualifies or simply adds uncertainty to the earlier observation. Carry that interpretation into both the discussion and the tabulated summary.
If the available report lacks the assay conditions needed to decide, identify the missing information. Do not describe the second experiment as a negative replication until the evidence supports that characterization. Route the resulting safety question to 2.4 rather than leaving it isolated in a table.
Use a study-role map to prevent selective summarizing
Classify each study by the question it was designed to answer before choosing the narrative order. The same assay technology can support different scientific questions, so an assay name alone is not a reliable classification rule.
| Working field | What to record | Why the writer needs it |
|---|---|---|
| Study role | Intended activity, secondary effect, safety concern or interaction | Prevents a target-activity result from being presented as an organ-safety assessment |
| System and controls | Species, tissue or assay system and relevant comparators | Shows whether apparently discordant findings are comparable |
| Concentration or dose basis | Tested range and what the reported measure represents | Prevents nominal concentration and measured exposure from being conflated |
| Material | Test-article identity and relevant characterization | Exposes a result generated with material different from the proposed product |
| Finding and limitation | Actual observation, report location and scientific qualification | Keeps negative or uncertain findings beside the interpretation |
This is an editorial study map rather than a required submission table. Build the tabulated summary using the applicable M4S formats, then use the working map to challenge omissions and inconsistent terminology.
When an experiment informs both intended activity and a safety concern, retain one study identifier and describe both roles. Do not count the same experiment twice as independent corroboration. If a later experiment is said to resolve an earlier signal, state what changed in the design or evidence and what remains uncertain.
Finish with a handoff to the nonclinical overview: the supported mechanism, material unwanted effects, unresolved disagreements and the limits of translation to human use. This is more useful than a statement that all planned pharmacology documents are complete.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
How do primary and secondary pharmacodynamics differ?
Primary pharmacodynamics concerns effects related to the intended therapeutic activity. Secondary pharmacodynamics examines effects beyond that intended activity. Classify the evidence using the study objective and scientific interpretation, not merely the assay name, and retain findings that qualify claims about selectivity or mechanism.
Can one study appear in more than one pharmacology discussion?
Yes, when it informs more than one scientific question. Preserve its single identity and cross-reference it clearly. Explain the different relevance in each discussion without making duplicated descriptions appear to be independent supporting experiments or inconsistent versions of the same result.
Can an in vitro potency result establish clinical efficacy?
No. A laboratory result supports an interpretation within the tested system and conditions. Describe what it shows about pharmacological activity and its limitations. Clinical benefit requires appropriate clinical evidence; changing the wording from “activity” to “efficacy” does not supply that evidence.
What should be checked between the written and tabulated pharmacology summaries?
Compare study identifiers, material, system, controls, concentration or dose basis, reported findings and important qualifications. A table can be numerically correct while the narrative omits a contradictory result. Check that the interpretation accounts for the relevant evidence, including unresolved differences between experiments.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4S(R2): Nonclinical overview and summaries ↗Step 4, December 20, 2002; sections 2.4 and 2.6 and Appendices A/B. FDA M4S and Safety Appendices remain labeled final, August 2001; ICH R2 includes subsequent editorial changes.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 2.6.2. A heading identifies placement, not mandatory applicability.